...
首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >Soluble factors from T cells inhibiting X4 strains of HIV are a mixture of β chemokines and RNases
【24h】

Soluble factors from T cells inhibiting X4 strains of HIV are a mixture of β chemokines and RNases

机译:T细胞抑制HIV X4菌株的可溶性因子是β趋化因子和RNase的混合物

获取原文
获取原文并翻译 | 示例
           

摘要

T-cell-derived soluble factors that inhibit both X4 and R5 HIV are recognized as important in controlling HIV. Whereas three β chemokines, regulated-on-activation normal T-cell expressed and secreted (RANTES), macrophage inflammatory protein (MIP)-1α, and MIP-1|i account for the suppression of R5 HIV by blockade of HIV entry, the major components responsible for the inhibition of X4 HIV strains have not been identified previously. We identify these factors primarily as a mixture of three β chemokines [macrophage-derived chemokine (MDC), thymus and activation-regulated che-mokine (TARC), and I-309] and two RNases (angiogenin and RNase 4) of lesser potency and show that in a clade B population, some correlate with clinical status and are produced by both CD4~+ and CD8~+ T cells (chemokines, angiogenin) or only by CD8~+ T cells (RNase 4). The antiviral mechanisms of these HIV X4-suppressive factors differ from those of the previously described HIV R5-suppressive β chemokines.
机译:抑制X4和R5 HIV的T细胞衍生可溶性因子被认为在控制HIV中很重要。鉴于三种β趋化因子,激活的正常T细胞表达和分泌调控(RANTES),巨噬细胞炎性蛋白(MIP)-1α和MIP-1 | i可以通过阻断HIV的进入来抑制R5 HIV,以前尚未发现负责抑制X4 HIV菌株的主要成分。我们确定这些因素主要是由三种β趋化因子[巨噬细胞衍生的趋化因子(MDC),胸腺和激活调节型趋化因子(TARC),以及I-309]和效力较低的两种核糖核酸酶(血管生成素和核糖核酸酶4)的混合物组成。并表明在进化枝B种群中,某些与临床状况相关,并且由CD4 +和CD8 + T细胞(趋化因子,血管生成素)或仅由CD8 + T细胞(RNase 4)产生。这些HIV X4抑制因子的抗病毒机制不同于先前描述的HIV R5抑制β趋化因子。

著录项

  • 来源
  • 作者单位

    Institute of Human Virology and Departments of University of Maryland School of Medicine, Baltimore, MD 21201,Medicine, University of Maryland School of Medicine, Baltimore, MD 21201;

    Institute of Human Virology and Departments of University of Maryland School of Medicine, Baltimore, MD 21201,Medicine, University of Maryland School of Medicine, Baltimore, MD 21201;

    Institute of Human Virology and Departments of University of Maryland School of Medicine, Baltimore, MD 21201,Medicine, University of Maryland School of Medicine, Baltimore, MD 21201;

    Institute of Human Virology and Departments of University of Maryland School of Medicine, Baltimore, MD 21201;

    Institute of Human Virology and Departments of University of Maryland School of Medicine, Baltimore, MD 21201,Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201;

    Institute of Human Virology and Departments of University of Maryland School of Medicine, Baltimore, MD 21201,Medicine, University of Maryland School of Medicine, Baltimore, MD 21201;

    Institute of Human Virology and Departments of University of Maryland School of Medicine, Baltimore, MD 21201,Medicine, University of Maryland School of Medicine, Baltimore, MD 21201;

    Institute of Human Virology and Departments of University of Maryland School of Medicine, Baltimore, MD 21201,Medicine, University of Maryland School of Medicine, Baltimore, MD 21201;

    Section of Infectious Diseases and Immunopathology, Department of Clinical Sciences, Luigi Sacco', University of Milan School of Medicine, 20157 Milan, Italy;

    Institute of Human Virology and Departments of University of Maryland School of Medicine, Baltimore, MD 21201,Medicine, University of Maryland School of Medicine, Baltimore, MD 21201;

    Institute of Human Virology and Departments of University of Maryland School of Medicine, Baltimore, MD 21201,Medicine, University of Maryland School of Medicine, Baltimore, MD 21201;

  • 收录信息 美国《科学引文索引》(SCI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    antiretroviral; lentivirus;

    机译:抗逆转录病毒慢病毒;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号